Metabolic Syndrome and Related Factors in Patients with Schizophrenia

Aim: To assess the prevalence rate of metabolic syndrome (MetS) in patients with schizophrenia and to determine related socio-demographic features and clinical characteristics. Methods: Fifty-five inpatients diagnosed with schizophrenia were included. A demographic and clinical data form was completed. The laboratory results were retrieved from the hospital information system. Patients' weight, height, waist circumference, and blood pressure were measured. The diagnosis of MetS was made based on the NCEP ATP III (Adult Treatment Protocol of the National Cholesterol Education Program), ATP III-A (Adapted) and IDF (International Diabetes Federation) criteria. Results: The prevalence rate of MetS was 38.2% according to the IDF and 25.5% based on ATP III and ATP III-A criteria. The mean age, duration of illness, length of medication use, and time between symptom onset and diagnosis were significantly higher in patients with schizophrenia with MetS (p